| Literature DB >> 29475397 |
Mi-Yeon Jung1, Jeong-Han Kang1, Danielle M Hernandez1, Xueqian Yin1, Mahefatiana Andrianifahanana1, Youli Wang2, Anatilde Gonzalez-Guerrico3, Andrew H Limper1, Ruth Lupu3, Edward B Leof1.
Abstract
Evidence is provided that the fibroproliferative actions of TGF-β are dependent on a metabolic adaptation that sustains pathologic growth. Specifically, profibrotic TGF-β signaling is shown to require fatty acid synthase (FASN), an essential anabolic enzyme responsible for the de novo synthesis of fatty acids. With the use of pharmacologic and genetic approaches, we show that TGF-β-stimulated FASN expression is independent of Smad2/3 and is mediated via mammalian target of rapamycin complex 1. In the absence of FASN activity or protein, TGF-β-driven fibrogenic processes are reduced with no apparent toxicity. Furthermore, as increased FASN expression was also observed to correlate with the degree of lung fibrosis in bleomycin-treated mice, inhibition of FASN was examined in a murine-treatment model of pulmonary fibrosis. Remarkably, inhibition of FASN not only decreased expression of profibrotic targets, but lung function was also stabilized/improved, as assessed by peripheral blood oxygenation.-Jung, M.-Y., Kang, J.-H., Hernandez, D. M., Yin, X., Andrianifahanana, M., Wang, Y., Gonzalez-Guerrico, A., Limper, A. H., Lupu, R., Leof, E. B. Fatty acid synthase is required for profibrotic TGF-β signaling.Entities:
Keywords: fibrosis; idiopathic pulmonary fibrosis; metabolism
Mesh:
Substances:
Year: 2018 PMID: 29475397 PMCID: PMC5998981 DOI: 10.1096/fj.201701187R
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191